Nuvectis Pharma, Inc.
NVCT
$0.17
Change (1 day)
$12.10
Year High
$4.44
Year Low
Categories
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Nuvectis Pharma, Inc. (NVCT) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -19,126,000 | 6.98 M | 19.19 M | 19.19 M | |
| 2022 | -19,993,000 | 6.19 M | 20.41 M | 20.41 M | |
| 2021 | -5,742,000 | 17.67 M | 6.66 M | 5.83 M | |
| 2020 | 10 K |